The Dutch government has donated 1.5 million euros to a clinical trial to investigate the therapeutic efficacy of CBD in the treatment of various forms of childhood epilepsy. This 4-year project will take place at the Teaching Hospital of the Brain Research Center of the University of Utrecht.
The study will use CBD oil derived from therapeutic plant varieties. Directly in the test will be used CBD extract Bedrolite, obtained from Bedrocan plants, under the brand name Dutch Transvaal. A set of 50 participants will start in the summer. The first tests will begin by the end of the year. Participants must have a confirmed diagnosis of an epileptic disease and no previous experience with cannabinoid use.
During the observation, the researchers will measure the effect of different servings of CBD oil on the manifestation of characteristic symptoms of epileptic diseases. In particular, physicians will look at the effects of the oil on the frequency and duration of seizures, as well as its effect on other indicators of the patient's quality of life, such as the depth and length of sleep.
“In this study, we plan to focus on the individual effectiveness of CBD in the treatment of a group of characteristic symptoms in patients with different forms of the disease. Thus, we are collecting more accurate information not so much about the overall effectiveness of CBD in the treatment of epilepsy, but its effectiveness in the treatment of various diseases, including more exotic subtypes,” one of the project curators, pediatrician and neurologist, Floor Jansen, tells the press.
"In addition to the effect of the substance on the frequency and intensity of seizures, we are also interested in its effect on the patient's vital signs, which is especially important in the field of pediatrics. The ability of CBD to have a tonic effect on children, as well as the ability to reduce the side effects of other therapeutic agents, will be a significant beneficial "bonus" of the use of cannabinoids."